Edwards Lifesciences Corp (EW)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Edwards Lifesciences Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 86.10 $ — 60% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 17.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 32
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3.00 | 2.96 – 3.05 | 6,759 | 17.1% | 28 |
| 12/31/2027 | 3.38 | 3.29 – 3.46 | 7,429 | 12.6% | 28 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.74 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.65 | 7.10 | 1,386 | 9.40 | 27.80 | 280 | 224 |
| 2025: Q1 | 0.61 | 4.60 | 1,413 | 6.20 | 25.30 | 280 | 224 |
| 2025: Q2 | 0.56 | -6.80 | 1,532 | 10.60 | 21.50 | 290 | 241 |
| 2025: Q3 | 0.50 | -90.30 | 1,553 | 14.70 | 18.70 | 574 | 516 |
| 2025: Q4 | 0.16 | -76.00 | 1,570 | 13.30 | 5.80 | 451 | 354 |
| 2026: Q1 | 0.66 | 7.60 | 1,649 | 16.70 | 23.10 | 44 | -21 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2,964 | 816 | 570 | 0.87 | 704 | 2,619 | 4,510 |
| 2017 | 3,435 | 1,010 | 622 | 0.96 | 1,001 | 2,995 | 5,697 |
| 2018 | 3,723 | 1,092 | 722 | 1.13 | 927 | 3,140 | 5,324 |
| 2019 | 4,348 | 1,198 | 1,047 | 1.64 | 1,179 | 4,148 | 6,488 |
| 2020 | 4,386 | 1,296 | 823 | 1.30 | 1,054 | 4,574 | 7,237 |
| 2021 | 5,233 | 1,610 | 1,503 | 2.38 | 1,732 | 5,836 | 8,503 |
| 2022 | 5,382 | 1,702 | 1,522 | 2.44 | 1,218 | 5,807 | 8,293 |
| 2023 | 6,005 | 1,534 | 1,402 | 2.30 | 896 | 6,650 | 9,363 |
| 2024 | 5,440 | 1,379 | 4,175 | 6.97 | 542 | 9,998 | 13,055 |
| 2025 | 6,068 | 1,636 | 1,074 | 1.83 | 1,595 | 10,338 | 13,697 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Edwards Lifesciences Corporation bietet Produkte und Technologien zur Behandlung fortgeschrittener Herz-Kreislauf-Erkrankungen in den USA, Europa, Japan und international an. Es bietet Transkatheter-Herzklappenersatzprodukte für den minimalinvasiven Ersatz von Aortenklappen unter der Marke Edwards an.
| Employees | 16,000 |
|---|---|
| Headquarters | Irvine, CA |
| Address | One Edwards Way, 92614 Irvine, United States |
| Phone | 949 250 2500 |
| Website | edwards.com |
| IPO Date | 27. Mar 2000 |
| ISIN | US28176E1082 |
| Stock Split | 3:1 on 06/01/2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Bernard J. Zovighian | CEO & Director | 1968 |
| Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development | 1962 |
| Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | 1979 |
| Annette Maria Bruls | Corporate Vice President of EMEA, Canada, & Latin America | 1971 |
| Theodora Mistras | Corporate VP & CFO | 1982 |
| Joseph Nuzzolese | Corporate Vice President of Global Operations & Quality | – |
| Andrew M. Dahl | Principal Accounting Officer, Senior VP & Corporate Controller | 1978 |
| Todd Brinton FACC, M.D. | Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer | – |
| Snehashish Sarkar | Senior VP and Chief Information & Digital Officer | 1975 |
| Mark D. Peterson | Corporate VP & General Counsel | 1963 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 30. Jul 2026 | Markowitz Wayne | CVP, JAPAC | Sell | 146 | 86.03 | 12,561 |
| 28. Jul 2026 | Markowitz Wayne | CVP, JAPAC | Sell | 9,628 | 85.06 | 818,958 |
| 28. Jul 2026 | Markowitz Wayne | CVP, JAPAC | Other | 9,628 | 74.02 | 712,665 |
| 27. Jul 2026 | Zovighian Bernard J | CEO | Sell | 2,921 | 83.93 | 245,172 |
| 27. Jul 2026 | Zovighian Bernard J | CEO | Other | 320 | 0.00 | – |
| 11. Jul 2026 | Bruls Annette | CVP, EMEACLA | Other | 109 | 92.21 | 10,051 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.